Actinium Pharmaceuticals, INC 8-K filings

Actinium Pharmaceuticals has submitted a compliance plan to NYSE American to regain compliance with listing standards related to stockholder equity.

Actinium Pharmaceuticals has received a notice of non-compliance from the NYSE American regarding stockholders' equity requirements.

Actinium Pharmaceuticals, Inc. announced its board's decision to hold annual shareholder advisory votes on executive compensation, aligning with shareholder preference.

Actinium Pharmaceuticals announces the resignation of its Chief Financial Officer, Steve O'Loughlin, with CEO Sandesh Seth assuming the principal financial officer duties.

Actinium Pharmaceuticals, Inc. announced the re-election of Class III directors and the approval of all proposals at its 2025 annual meeting of stockholders.

Actinium Pharmaceuticals dismisses Marcum LLP as its independent auditor due to its acquisition by CBIZ CPAs, and subsequently engages CBIZ CPAs as its new auditor.

Actinium Pharmaceuticals successfully re-elected two Class II directors and ratified its independent auditor at its 2024 annual meeting.

Actinium Pharmaceuticals has appointed seasoned biopharma executive June Almenoff, M.D., Ph.D., to its Board of Directors, bringing over 25 years of drug development and leadership experience.

The FDA has determined that Actinium's Phase 3 SIERRA trial for Iomab-B is insufficient for BLA filing, requiring an additional head-to-head trial demonstrating overall survival benefit.